Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
11.09. | Amid restructuring, Novo Nordisk directs employees to return to office | ||
11.09. | AbbVie settles with generic Rinvoq hopefuls, shielding the immunology med's US stronghold until 2037 | ||
11.09. | Intercept, after many setbacks, pulls liver disease drug Ocaliva in US | ||
11.09. | Despite being designed for seniors, Merck's pneumococcal shot shows potential in children | ||
11.09. | FibroGen pays SEC $1.2M over allegations former exec 'reverse engineered' roxadustat data | ||
11.09. | Chicago private equity firm inks €4.1B purchase of former Sanofi generics unit Zentiva: FT | ||
11.09. | Sun's Gujarat facility put on FDA import alert for persistent production shortfalls | ||
11.09. | Sanofi, Gilead, Acadia win big at the 2025 Fierce Pharma Marketing Awards | ||
11.09. | API maker Hikal hit with FDA warning letter after repeat contamination complaints | ||
10.09. | Editor's Corner-For the first PD-1xVEGF's sake, Summit must submit to Big Pharma, stat | ||
10.09. | For pharmas looking to 'break through the clutter' and reach patients, relatability is the key | ||
10.09. | 'Land mines everywhere': How pharma communications keep up under a political spotlight | ||
10.09. | Sanofi rounds up 'celebrity mom squad' for Beyfortus RSV campaign | ||
10.09. | Trump directs FDA to limit DTC drug advertising, with legal challenges sure to follow | ||
10.09. | J&J's 'practice-changing' bladder cancer drug-device combo Inlexzo lands FDA nod | ||
10.09. | Trump admin mulls 'severe restrictions' on US pharmas licensing Chinese meds: NYT | ||
10.09. | Eli Lilly gives Julianne Moore a new role, signing up Oscar winner for brain health campaign | ||
10.09. | Novo Nordisk to lay off 9,000 workers as new CEO aims to save $1.3B per year by late 2026 | ||
10.09. | Takeda faces another 'pay-for-delay' antitrust lawsuit, this one from CVS over heartburn drug Dexilant | ||
09.09. | 'We want to feel heard': Jamie-Lynn Sigler on how pharmas can better serve patients | ||
09.09. | Lundbeck, in major resource reallocation, bows out of 27 markets and lays off 602 staffers | ||
09.09. | Permira looks to launch $4B sale of CDMO Cambrex: FT | ||
09.09. | Novo, Lilly obesity meds 'highly cost-effective' but sure to strain payer budgets: ICER report | ||
09.09. | With settlement, Sandoz can launch its biosimilar to Regeneron's Eylea by end of 2026 | ||
09.09. | Endo touts Xiaflex success stories in inaugural Dupuytren's contracture awareness month |